Document is current

Any future updates will be listed below

Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy

Crossref DOI link: https://doi.org/10.1186/s40164-018-0114-9

Published Online: 2018-09-06

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark